A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)

Stopped early · Phase 4

Conditions studied: Macular Degeneration

In brief

The purpose of this trial is to compare the ability of three different doses of pegaptanib sodium to safely and effectively minimize fluid leakage within the eye, thereby stabilizing or improving vision in patients with wet AMD. The study will also examine the effects of pegaptanib sodium on the cornea and sensory retina of patients with wet AMD.

Key facts

Study ID

NCT00312351

Run by

Eyetech Pharmaceuticals

People needed

262

Starts

2006-04-01

Expected to finish

2006-11-01

Last updated by the study team

2007-01-15

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects of either gender, aged 50 years or greater.
• Subfoveal choroidal neovascularization (CNV) due to AMD.
• Best corrected visual acuity in the study eye between 20/40 and 20/320.
• Normal electroretinogram, and corneal endothelial cell density of 1500 cells/mm2 or more.

You may not qualify if…

• Any prior photodynamic therapy (PDT) with Visudyne or thermal laser to the study eye.

Where it is running

• Charlotte Eye, Ear, Nose and Throat Associates, P.A. — Charlotte, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.